{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000006","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.626854+00:00","generated_at":"2026-05-27T08:24:59.446462+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027","bullets":["Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.","Expects $7.0-8.0M in one-time termination costs in Q1 2025.","Believes cash runway extended into late 2027, beyond potential azenosertib data readout.","Registration-enabling DENALI Part 2 data readout anticipated by end of 2026.","Corporate event on Jan 29, 2025, to present azenosertib clinical data and regulatory update."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000006","json":"https://secwatch.observer/filing/0001725160-25-000006.json","markdown":"https://secwatch.observer/filing/0001725160-25-000006.md","text":"https://secwatch.observer/filing/0001725160-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/0001725160-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/zntl-20250122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:24:59.446462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66af16a6bac9ec89bf71eef7027c38a5ceb34876","claim":"Zentalis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $7.0–8.0 million affecting the Company (approximately 40%).","evidence_excerpt":"On January 22, 2025, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) approved a strategic restructuring of the Company to support execution of late-stage development for the Company’s WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticipated by the end of 2026. In connection with this strategic restructuring, the Company expects to reduce its workforce by approximately 40%. The Company expects to incur one-time costs of approximately $7.0–8.0 million in the first quarter of 2025 in connection with the workforce reduction.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/0001725160-25-000006-index.htm","confidence":0.4,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $7.0–8.0 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 40%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}